MS treatment – plans for induced pain drug INT0010
Posted: Wed Dec 01, 2010 1:05 am
IntelGenx Corp. announced that it has acquired exclusive rights to, and ownership of, INT0010, an improved formulation of THC (dronabinol) for the symptomatic management of Multiple Sclerosis (MS) induced neuropathic pain and chemotherapy induced nausea. These markets are multi-billion dollar markets worldwide, and believed to be growing.
IntelGenx entered into a royalty based licensing agreement with PediPharm Ltd. Under the terms of the agreement, IntelGenx has obtained worldwide rights to US Patent 7,592,328 and all corresponding foreign patents and patent applications to exclusively develop and further provide intellectual property protection for INT0010. PediPharm would receive a signing fee and a milestone payment upon IntelGenx securing a commercialisation partner for the product, along with a royalty from all sales of the product world-wide....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1815
IntelGenx entered into a royalty based licensing agreement with PediPharm Ltd. Under the terms of the agreement, IntelGenx has obtained worldwide rights to US Patent 7,592,328 and all corresponding foreign patents and patent applications to exclusively develop and further provide intellectual property protection for INT0010. PediPharm would receive a signing fee and a milestone payment upon IntelGenx securing a commercialisation partner for the product, along with a royalty from all sales of the product world-wide....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1815